Cytokinetics | CYTK - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Arca Biopharma USD -34.43M 326K 2025-12
Bayer EUR 1.11B 1.65B 2025-12
Biogen USD 659.6M 192.2M 2025-09
Brainstorm Cell Therapeutics USD -2.05M 526K 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Capricor Therapeutics USD -29.16M 2.87M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Exelixis USD 235.91M 20.45M 2025-12
Geron USD -10.79M 3.1M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
Merck USD 6.24B 318M 2025-12
Novartis USD 4.5B 363M 2025-09
Pfizer USD 4.65B 3.99B 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12